{"entity":{"type":"insider","cik":"0001276700","url":"/insider/0001276700","json_url":"/insider/0001276700.json","name":"KARBE FRANK","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":21,"first":"2008-10-31","last":"2024-12-16","span_basis":"filed_date"},"name_variants":[{"name":"KARBE FRANK","source":"filing","n_filings":21,"first_seen":"2008-10-31","last_seen":"2024-12-16"}],"transactions":[{"id":2394883,"accession":"0000950170-24-136391","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-136391","line_url":"/filing/0000950170-24-136391#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Phathom Pharmaceuticals, Inc.","issuer_ticker":"PHAT","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12500.0,"shares_display":"12,500","price_per_share":7.9267,"price_display":"7.93","price_state":"stated","total_value":99083.75,"total_display":"99,083.75","total_whole":"99,084","shares_owned_after":57000.0,"shares_owned_after_display":"57,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-13","filed_date":"2024-12-16","scope":"insider"},{"id":8137472,"accession":"0000950170-23-035680","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-035680","line_url":"/filing/0000950170-23-035680#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Better Therapeutics, Inc.","issuer_ticker":"BTTX","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":137005.0,"shares_display":"137,005","price_per_share":0.7299,"price_display":"0.73","price_state":"stated","total_value":99999.9495,"total_display":"99,999.95","total_whole":"100,000","shares_owned_after":429429.0,"shares_owned_after_display":"429,429","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-27","filed_date":"2023-07-31","scope":"insider"},{"id":8388374,"accession":"0000899243-23-011189","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-011189","line_url":"/filing/0000899243-23-011189#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Better Therapeutics, Inc.","issuer_ticker":"BTTX","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":242424.0,"shares_display":"242,424","price_per_share":0.825,"price_display":"0.82","price_state":"stated","total_value":199999.8,"total_display":"199,999.80","total_whole":"200,000","shares_owned_after":292424.0,"shares_owned_after_display":"292,424","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-10","filed_date":"2023-04-12","scope":"insider"},{"id":6443976,"accession":"0000899243-22-031206","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-031206","line_url":"/filing/0000899243-22-031206#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Better Therapeutics, Inc.","issuer_ticker":"BTTX","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":2.0939,"price_display":"2.09","price_state":"stated","total_value":104695.0,"total_display":"104,695.00","total_whole":"104,695","shares_owned_after":50000.0,"shares_owned_after_display":"50,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-15","filed_date":"2022-09-15","scope":"insider"},{"id":4275134,"accession":"0001209191-21-046171","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-046171","line_url":"/filing/0001209191-21-046171#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3232.0,"shares_display":"3,232","price_per_share":21.75,"price_display":"21.75","price_state":"stated","total_value":70296.0,"total_display":"70,296.00","total_whole":"70,296","shares_owned_after":212296.0,"shares_owned_after_display":"212,296","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-07","filed_date":"2021-07-09","scope":"insider"},{"id":4092402,"accession":"0001209191-21-026084","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-026084","line_url":"/filing/0001209191-21-026084#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11080.0,"shares_display":"11,080","price_per_share":18.63,"price_display":"18.63","price_state":"stated","total_value":206420.4,"total_display":"206,420.40","total_whole":"206,420","shares_owned_after":152390.0,"shares_owned_after_display":"152,390","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-06","filed_date":"2021-04-08","scope":"insider"},{"id":5488726,"accession":"0001209191-21-011894","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-011894","line_url":"/filing/0001209191-21-011894#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":21.4,"price_display":"21.40","price_state":"stated","total_value":16050.0,"total_display":"16,050.00","total_whole":"16,050","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-16","filed_date":"2021-02-18","scope":"insider"},{"id":4257422,"accession":"0001209191-21-006444","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-006444","line_url":"/filing/0001209191-21-006444#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":24.0,"price_display":"24.00","price_state":"stated","total_value":7200.0,"total_display":"7,200.00","total_whole":"7,200","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-28","filed_date":"2021-02-01","scope":"insider"},{"id":5189522,"accession":"0001209191-21-004328","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-004328","line_url":"/filing/0001209191-21-004328#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":16125.0,"total_display":"16,125.00","total_whole":"16,125","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-15","filed_date":"2021-01-20","scope":"insider"},{"id":2226951,"accession":"0001209191-20-065511","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-065511","line_url":"/filing/0001209191-20-065511#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11800.0,"shares_display":"11,800","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":354000.0,"total_display":"354,000.00","total_whole":"354,000","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-28","filed_date":"2020-12-30","scope":"insider"},{"id":2120699,"accession":"0001209191-20-064096","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-064096","line_url":"/filing/0001209191-20-064096","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1050.0,"shares_display":"1,050","price_per_share":24.154955238095237,"price_display":"24.15","price_state":"stated","total_value":25362.703,"total_display":"25,362.70","total_whole":"25,363","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-15","filed_date":"2020-12-17","scope":"insider","n_lines":2},{"id":2346294,"accession":"0001209191-20-061221","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-061221","line_url":"/filing/0001209191-20-061221#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":24.0,"price_display":"24.00","price_state":"stated","total_value":36000.0,"total_display":"36,000.00","total_whole":"36,000","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-30","filed_date":"2020-12-02","scope":"insider"},{"id":2691248,"accession":"0001209191-20-059450","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-059450","line_url":"/filing/0001209191-20-059450#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":15000.0,"total_display":"15,000.00","total_whole":"15,000","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-17","filed_date":"2020-11-19","scope":"insider"},{"id":2252564,"accession":"0001209191-20-058894","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-058894","line_url":"/filing/0001209191-20-058894#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":15000.0,"total_display":"15,000.00","total_whole":"15,000","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-13","filed_date":"2020-11-17","scope":"insider"},{"id":2145512,"accession":"0001209191-20-050887","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-050887","line_url":"/filing/0001209191-20-050887#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":21.73,"price_display":"21.73","price_state":"stated","total_value":16297.5,"total_display":"16,297.50","total_whole":"16,298","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-15","filed_date":"2020-09-17","scope":"insider"},{"id":2381906,"accession":"0001209191-20-048927","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-048927","line_url":"/filing/0001209191-20-048927#line-4","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21150.0,"shares_display":"21,150","price_per_share":20.013,"price_display":"20.01","price_state":"stated","total_value":423274.95,"total_display":"423,274.95","total_whole":"423,275","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-31","filed_date":"2020-09-01","scope":"insider"},{"id":2381900,"accession":"0001209191-20-048927","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-048927","line_url":"/filing/0001209191-20-048927#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3650.0,"shares_display":"3,650","price_per_share":20.04,"price_display":"20.04","price_state":"stated","total_value":73146.0,"total_display":"73,146.00","total_whole":"73,146","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-28","filed_date":"2020-09-01","scope":"insider"},{"id":2111730,"accession":"0001209191-20-047968","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-047968","line_url":"/filing/0001209191-20-047968#line-2","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":700.0,"shares_display":"700","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":14000.0,"total_display":"14,000.00","total_whole":"14,000","shares_owned_after":163470.0,"shares_owned_after_display":"163,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-19","filed_date":"2020-08-21","scope":"insider"},{"id":8601894,"accession":"0001209191-19-062187","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-062187","line_url":"/filing/0001209191-19-062187#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19701.0,"shares_display":"19,701","price_per_share":15.55,"price_display":"15.55","price_state":"stated","total_value":306350.55,"total_display":"306,350.55","total_whole":"306,351","shares_owned_after":43324.0,"shares_owned_after_display":"43,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-30","filed_date":"2019-12-30","scope":"insider"},{"id":7805404,"accession":"0001209191-19-036115","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-036115","line_url":"/filing/0001209191-19-036115#line-1","is_derivative":false,"issuer_cik":"0001276700","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001276700","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (Principal Fin'l & Accounting)","role_mark":"O","role_mark_label":"Officer (Principal Fin'l & Accounting)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Principal Fin'l & Accounting","security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8000.0,"shares_display":"8,000","price_per_share":9.1,"price_display":"9.10","price_state":"stated","total_value":72800.0,"total_display":"72,800.00","total_whole":"72,800","shares_owned_after":8000.0,"shares_owned_after_display":"8,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-06-11","filed_date":"2019-06-11","scope":"insider"},{"id":7688219,"accession":"0001140361-10-035051","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-10-035051","line_url":"/filing/0001140361-10-035051","is_derivative":false,"issuer_cik":"0000939767","issuer_name":"EXELIXIS INC","issuer_ticker":"EXEL","issuer_name_source":null,"issuer_url":"/issuer/0000939767","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (EVP & CFO)","role_mark":"O","role_mark_label":"Officer (EVP & CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16500.0,"shares_display":"16,500","price_per_share":2.979709090909091,"price_display":"2.98","price_state":"stated","total_value":49165.2,"total_display":"49,165.20","total_whole":"49,165","shares_owned_after":60110.0,"shares_owned_after_display":"60,110","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-08-24","filed_date":"2010-08-25","scope":"insider","n_lines":3},{"id":3819829,"accession":"0001140361-08-024157","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-08-024157","line_url":"/filing/0001140361-08-024157","is_derivative":false,"issuer_cik":"0000939767","issuer_name":"EXELIXIS INC","issuer_ticker":"EXEL","issuer_name_source":null,"issuer_url":"/issuer/0000939767","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (EVP, CFO)","role_mark":"O","role_mark_label":"Officer (EVP, CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":3.3666666666666667,"price_display":"3.37","price_state":"stated","total_value":25250.0,"total_display":"25,250.00","total_whole":"25,250","shares_owned_after":28840.0,"shares_owned_after_display":"28,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-10-31","filed_date":"2008-10-31","scope":"insider","n_lines":2},{"id":3819825,"accession":"0001140361-08-024157","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-08-024157","line_url":"/filing/0001140361-08-024157","is_derivative":false,"issuer_cik":"0000939767","issuer_name":"EXELIXIS INC","issuer_ticker":"EXEL","issuer_name_source":null,"issuer_url":"/issuer/0000939767","owner_cik":"0001276700","owner_name":"KARBE FRANK","owner_display_name":"KARBE FRANK","owner_url":"/insider/0001276700","role":"Officer (EVP, CFO)","role_mark":"O","role_mark_label":"Officer (EVP, CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":3.2125,"price_display":"3.21","price_state":"stated","total_value":32125.0,"total_display":"32,125.00","total_whole":"32,125","shares_owned_after":21340.0,"shares_owned_after_display":"21,340","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-10-30","filed_date":"2008-10-31","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":28,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":12,"open_market":true},{"code":"S","label":"Open-market sale","n":16,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":28},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001783183","name":"Phathom Pharmaceuticals, Inc.","url":"/issuer/0001783183","role":"Director","n_filings":1,"first_seen":"2024-12-16","last_seen":"2024-12-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001832415","name":"Better Therapeutics, Inc.","url":"/issuer/0001832415","role":"Director, Officer (Chief Executive Officer)","n_filings":3,"first_seen":"2022-09-15","last_seen":"2023-07-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Officer (Principal Fin'l & Accounting)","n_filings":15,"first_seen":"2019-06-11","last_seen":"2021-07-09"},{"type":"issuer","type_label":"ISSUER","cik":"0000939767","name":"EXELIXIS INC","url":"/issuer/0000939767","role":"Officer (EVP & CFO)","n_filings":2,"first_seen":"2008-10-31","last_seen":"2010-08-25"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001276700","retrieved_at":"2026-08-23T16:49:56+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}